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esponsibility of InstAbstract The previous investigation has proved that their existed pharmacokinetic difference between the
different crystal forms of the polymorphic drugs after oral administration. However, no systemic investigations
have been made on the change of this pharmacokinetic difference, resulted either from the physiological or from
the pathological factors. In this paper, we used polymorphic nimodipine (Nim) as a model drug and investigated
the effect of age difference (2- and 9-month old) on the pharmacokinetics after oral delivery in rats. As the
results shown, for L-form of Nim (L-Nim), the AUC0–24 h in 2-month-old rats was 343.68747.15 ng  h/mL,
which is 23.36% higher than that in 9-month-old rats. For H-form of Nim (H-Nim), the AUC0–24 h in 2-month-
old rats was 140.91719.47 ng  h/mL, which is 54.64% higher than that in 9-month-old rats. The AUC0–24 h
ratio between H-Nim and L-Nim was 2.44 in 2-month-old rats and 3.06 in 9-month-old rats. Since age
difference could result in unparallelled change of the absorption and bioavailability of the polymorphic drugs,
the results in this experiment are of value for further investigation of crystal form selection in clinical trials and
rational clinical application of the polymorphic drugs.
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According to the previous investigation, the in vivo absorption and
bioavailability of polymorphic drugs may be different due to the
crystal form modiﬁcation, which usually result in the change of the
physical and chemical properties1–3. Wang et al.4 reported that
after oral administration of A and B polymorphs of m-nisoldipine
to rats, the area under the plasma concentration-time curve (AUC)
of m-nisoldipine B was 1.17-fold higher than that of A, the
maximum plasma concentration (Cmax) and the time to reach a
Cmax (Tmax) values showed statistically signiﬁcant differences
between m-nisoldipine A and B. They concluded that the crystal
form could inﬂuence the rate and extent of absorption and
bioavailability of m-nisoldipine. Du et al.5 investigated the
in vitro and in vivo correlation of Forms I, II and III of
agomelatine, and found that the agomelatine polymorphic forms
with faster dissolution rates in vitro would increase the rate and
extent of oral absorption in vivo.
So far, numerous works have proved the physiological and
pathological effects on the absorption and elimination of non-
polymorphic drugs. These inﬂuencing factors generally refer to
age, diabetes, nephropathy and hepatopathy6–9. Considering the
factor of age, possible reasons for these pharmacokinetic changes
are diverse and complex. Natural developmental maturation and
aging of gastrointestinal tract, liver and renal could lead to
different changes in drug absorption, metabolism and clearance,
and transport and elimination10–14. A recent population pharma-
cokinetic study showed statistically signiﬁcant differences in
carbamazepine pharmacokinetics between elderly and relatively
young epileptic patients15. Tarral and Merdjan16 noted the
prolonged elimination half-life of oral minodronic acid in elderly
subjects and they concluded that it could be due to the reduced
renal function. As Zhou et al.17 reported, the higher exposure of
minodronic acid in the elderly subjects could be attributed to the
reduction of renal blood ﬂow, glomerular ﬁltration rate and the
bone uptake of the elderly.
According to the above investigations, the oral bioavailability
of different crystal forms in healthy subjects might vary upon the
physiological status. However, so far, little work has been done on
the investigation as how the physiological factors inﬂuence the
pharmacokinetics of the polymorphic drugs. Nim has high perme-
ability and poor solubility, which belongs to Class II of the
Biopharmaceutical Classiﬁcation System18. Moreover, Nim is a
kind of polymorphic drug presenting two different crystal forms,
including H-Nim and L-Nim. As Grunenberg et al.18 reported,
H-Nim, a meta-stable form, is a racemic compound that exhibits a
characteristic melting point at 124 1C, while L-Nim, a stable form,
is a conglomerate that melts at 116 1C.
In this experiment, the effect of age on the pharmacokinetic
properties of polymorphic drug was investigated in rats of 2- or 9-
month old with Nim as a model polymorphic drug. The work may
help us to choose the suitable crystal form of the polymorphic
drugs in their dosage form design, clinical trial, as well as the
rational clinical application.2. Materials and methods
2.1. Materials
H-Nim (99.3%) was kindly supplied by Ruikang Pharmaceutical
Co., Ltd. (Zhengzhou, China). L-Nim was prepared byrecrystallization of H-Nim in diethyl ether in our laboratory.
Methanol and acetonitrile of HPLC grade were purchased from
Tianjin Jiangtian Chemical Technology Co., Ltd. (Tianjin, China).
Diethyl ether was obtained from Real & Lead Chemical Co., Ltd.
(Tianjin, China). All other reagents used were either of analytical
or chromatographic grades. Nitrendipine as an internal standard
was purchased from National Institutes for Food and Drug Control
(Beijing, China).
2.2. Preparation of polymorphic Nim
H-Nim was sieved and the received powder with a particle size
between 120 and 150 μm was used for further investigation.
L-Nim was prepared by recrystallization of H-Nim in ethyl ether.
Generally, 1.0 g H-Nim was dissolved in 50 mL of ethyl ether at
30 1C to get a solution and then the solvent was evaporated by
manually stirring with a glass rod in a draft cupboard in a water bath
at 25 1C until a faint yellow powder was received. The obtained
L-Nim was then stored in a desiccator for 24 h. The received L-Nim
was sieved and the received powder with a particle size between 120
and 150 μm was used for further investigation.
2.3. Characterization of H-Nim and L-Nim
2.3.1. X-ray diffraction (XRD)
An X-ray diffractometer (X'Pert Pro, PANalytical B.V., Nether-
lands) with Cu-Kα radiation of wavelength 1.5406 Å (40 kV,
40 mA) was employed to study the crystalline form of H-Nim and
L-Nim. The samples were then analyzed over a 2θ range of 2–351
with a scanning rate of 81/min and step size of 0.02.
2.3.2. Differential scanning calorimetry (DSC)
Thermal analysis was carried out using a differential scanning
calorimeter (DSC 1/500, Mettler-Toledo, Switzerland) for H-Nim
and L-Nim. Samples in sealed aluminum pans were scanned from
25 to 150 1C with a heating rate of 10 1C/min under a dry
nitrogen purge.
2.4. In vitro dissolution study
The dissolution of H-Nim and L-Nim in the medium of simulated
gastric ﬂuid (SGF, pH¼1.2 HCl) at 3770.5 1C were investigated
with the paddle method at the rotation speed of 50 rpm using a
dissolution apparatus (Type RC806, Tianda Tianfa Technology Co.,
Ltd., Tianjin, China). Thirty mg of drugs were dispersed into
250 mL of the dissolution medium. At the determined time points, a
5 mL aliquot of sample was withdrawn and ﬁltered through 0.22-μm
membrane ﬁlter. The ﬁltered samples were ﬁnally assayed by UV
spectrophotometry at 238 nm (UV765, Shanghai Precision Scientiﬁc
Instrument Co., Ltd., China). Each test was conducted in triplicates.
The concentration of Nim was calculated relative to a Nim reference
of y¼0.0592xþ0.0058 with r2 (correlation coefﬁcient) value of
0.9998 (x is the concentration of Nim in μg/mL and y is the
absorbance).
2.5. Pharmacokinetic study
Male Sprague–Dawley rats were obtained from the center for
experimental animal reproduction, Academy of Military Medical
Sciences, Tianjin, China. All animals received care in compliance
with the guidelines outlined in the Guide for the Care and Use of
Wenli Liu et al.470Laboratory Animals and all procedures were approved by
the Animal Care and Use Committee of Tianjin University. Ten
2-month-old rats weighted 250725 g and ten 9-month-old rats
with an average weight of 500725 g were used in the experiment.
The rats were maintained on a standard diet with free access to
water. And all rats were fasted for 12 h before the experiment but
had free access to drinking water. Each animal received a dose of
40 mg/kg H-Nim and L-Nim in the form of dry powder by
intragastric administration through a special pipeline connected
with an injector nozzle. Four hours after dosing, the rats were
provided with standard food.
Approximately 250 μL blood samples were withdrawn from the
oculi chorioideae vein before and 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0,
4.0, 6.0, 8.0, 10.0, 12.0 and 24.0 h after dosing. The blood samples
were immediately transferred into a heparinized Eppendorf tube and
centrifuged at 12,000 g for 5 min, and then the plasma was
obtained. All the plasma samples were stored at 20 1C until
analysis.
2.6. HPLC analysis
The HPLC analysis was carried out on a LabAlliance Model 2000
HPLC system (Tianjin Lanbo Experimental Equipment Co., Ltd.,
Tianjin, China). The separation was performed on a Kromasil C18
column (250 mm 4.6 mm, 5 μm) preceded by a same type C18
pre-column (10 mm 4.6 mm, 5 μm). The ﬂow rate was kept
constant at 1.0 mL/min and the temperature of oven was main-
tained at ambient temperature. The mobile phase used in the
separation of Nim was acetonitrile–water (70:30, v/v). The detec-
tion wavelength was set at 238 nm.
The method was validated in terms of speciﬁcity, linearity,
precision, extract recovery and stability. The blank plasma had no
interference with analysis of Nim or nitrendipine. The linear
regression of the peak area ratios versus concentrations was ﬁtted
over the concentration range of 5–320 ng/mL for Nim in plasma.
A typical regression equation for the calibration curve was:
y¼0.0084xþ0.0089, r2¼0.9999, where y is the peak area ratio
of Nim to nitrendipine, and x is the concentration of Nim in
plasma. The limit of quantiﬁcation of Nim in plasma was 5 ng/mL.
The intra-day and inter-day precisions were below 4.7%. The
average extraction recovery of Nim and nitrendipine in plasma
were 85.2% and 79.0%, respectively. The mean relative errors of
Nim concentration measured in quality control samples beingFigure 1 XRD patterns (A) and DSC thsubjected to certain conditions ranged from 6.5% to 7.3%,
which indicated the stability of Nim in plasma stored at room
temperature for 24 h, at 20 1C for 30 days and during the three
freeze–thaw cycles (20 1C and room temperature, repectively).
2.7. Plasma sample preparation
A 10 μL aliquot of internal standard solution (nitrendipine, 800 ng/mL
in methanol) and 500 μL methanol were added to 100 μL plasma
sample, which was then vortex-mixed for 1 min, disposed in an
ultrasonic bath for 5 min and centrifuged at 12,000 g for 10 min. The
upper organic layer was evaporated to dryness under a gentle stream of
nitrogen at 45 1C. The residue was reconstituted in 100 μL 30%
methanol solution, vortex-mixed for 3 min and centrifuged at
12,000 g for 15 min. Aliquots (25 μL) of the supernate were injected
into the HPLC system for analysis.
2.8. Statistical analysis
The main pharmacokinetic parameters were estimated by non-
compartmental methods using the software of DAS 2.0, including
the maximum plasma concentration (Cmax), the time to reach a Cmax
(Tmax), elimination rate constant (Ke), half-life (t1/2), clearance rate
(CL), apparent volume of distribution (Vd), mean residence time
(MRT0–24 h), the area under the plasma concentration-time curve
from time zero to inﬁnity (AUC0–1), the area under the plasma
concentration-time curve from time zero to the measured time t in
plasma (AUC0–t). Statistical analysis was carried out through
independent sample t-test. The statistical evaluation of the results
was performed in SPSS statistical software program (SPSS 17.0,
SPSS Inc., USA). Numerical values in tables and ﬁgures were
presented as mean7standard deviation (SD). Means were consid-
ered to be statistically signiﬁcant when Po0.05.3. Results
3.1. Characterization of H-Nim and L-Nim by XRD and DSC
As shown in Fig. 1A, the XRD patterns showed very different
diffractograms for H-Nim and L-Nim, especially at low 2θ angles,
which showed easy distinction between the two polymorphs.
Major characteristic diffraction peaks of H-Nim were observedermograms (B) of H-Nim and L-Nim.
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characteristic diffraction peaks at 2θ of 10.31, 19.41 and 20.71.
As shown in Fig. 1B, the DSC thermograms of H-Nim and L-Nim
showed melting endothermic peaks at 125 1C and 114 1C,
respectively.3.2. In vitro dissolution study
Dissolution proﬁles of H-Nim and L-Nim were shown in Fig. 2.
Generally, the dissolution rate of L-Nim was much faster than that
of H-Nim. For example, the accumulative percent drug released of
L-Nim at 30 min was 4.15%, which showed 4.51-fold higher than
that of H-Nim (0.92%, Po0.05). At the end of assay, the
cumulative percent drug released of H-Nim and L-Nim were
5.27% and 2.22%, respectively, with the former 2.37-fold higher
than that of the latter (Po0.01).Figure 2 Dissolution proﬁles of H-Nim and L-Nim in the dissolution
medium of SGF. Data are expressed as Mean7SD, n¼3. *Po0.05,
**Po0.01 compared to H-Nim.
Figure 3 Mean plasma concentration-time proﬁles of H-Nim and L-Nim i
Mean7SD, n¼5.3.3. The effect of polymorphism on the Pharmacokinetics of Nim
Mean plasma concentration-time proﬁles of H-Nim and L-Nim in
2-month-old and 9-month-old rats were shown in Fig. 3. The
pharmacokinetic parameters of H-Nim and L-Nim in 2-month-old
and 9-month-old rats were listed in Table 1. As shown in Fig. 3A, the
plasma concentration of H-Nim and L-Nim in 2-month-old rats
gradually increased up to the maximum value at 2.5 and 4 h,
respectively, then both went down gradually. As shown in Fig. 3B,
the plasma concentration of H-Nim and L-Nim in 9-month-old rats
reached peaks at 1.5 and 2 h, respectively, and then declined
gradually. In Table 1, compared with the pharmacokinetic parameters
of H-Nim in the two rat groups, AUC0–24 h, Cmax and Tmax of L-Nim
were signiﬁcantly increased (Po0.05), but the CL value of L-Nim
was remarkably decreased (Po0.05). Although the Vd value had no
signiﬁcant difference between H-Nim and L-Nim in 2-month-old rats,
the Vd value of L-Nim was signiﬁcantly lower than that of H-Nim in
9-month-old rats (Po0.05). Meanwhile, the other parameters,
MRT0–24 h and t1/2 were not signiﬁcantly different between H-Nim
and L-Nim both in 2-month-old and 9-month-old rats.3.4. The effect of age on the Pharmacokinetics of Nim
As shown in Fig. 3, the plasma concentration of H-Nim in 2-
month-old and 9-month-old rats presented peaks at 2.5 and 1.5 h,
respectively. The plasma concentration of L-Nim in 2-month-old
and 9-month-old rats reached peaks at 4 and 2 h, respectively. In
Table 1, the Cmax of H-Nim and L-Nim in 2-month-old rats were
26.2975.00 ng/mL and 41.9376.34 ng/mL, respectively, which
showed 1.73- and 1.27-fold higher than that of Cmax
(15.1671.62 ng/mL and 32.8873.59 ng/mL) in 9-month-old rats
(Po0.05). Furthermore, the Tmax of H-Nim and L-Nim in 2-
month-old rats were signiﬁcantly longer than that in 9-month-old
rats (Po0.05). However, although the AUC0–24 h of H-Nim in 2-
month-old rats was signiﬁcantly higher than that in 9-month-old
rats (Po0.05), the AUC0–24 h of L-Nim in 2-month-old rats was
just slightly higher than that in 9-month-old rats. Similarly, there
were no signiﬁcant differences of CL values of H-Nim and L-Nimn 2-month-old rats (A) and 9-month-old rats (B). Data are expressed as
Table 1 Pharmacokinetic parameters of H-Nim and L-Nim after oral administration at the dose of 40 mg/kg to 2-month-old rats and
9-month-old rats.
Pharmacokinetic parameter 2-month-old rats 9-month-old rats
H-Nim L-Nim H-Nim L-Nim
AUC0–24 h (ng  h/mL) 140.91719.47Δ 343.68747.15n 91.12722.83 278.58755.74*
AUC0-1 (ng  h/mL) 159.27744.00 400.61737.32* 123.00743.14 321.81750.91*
MRT0–24 h (h) 7.24371.62 8.0670.63 8.1670.84 7.74370.66
t1/2 (h) 6.0370.22 9.0672.90 6.8571.76 8.0074.15
CL (L/h/kg) 263.73757.70 100.4778.40* 362.287142.06 127.15722.69*
Vd (L/kg) 2007.397746.75 1324.107480.44 3923.7371529.70 1465.057768.83*
Cmax (ng/mL) 26.2975.00
Δ 41.9376.34*,Δ 15.1671.62 32.8873.59*
Tmax (h) 2.4070.42
Δ 5.0072.00Δ 1.5070.35 2.1070.42*
nPo0.05 compared to H-Nim; ΔPo0.05 compared to 9-month-old rats.
Wenli Liu et al.472between 2-month-old and 9-month-old rats. Furthermore, statisti-
cally insigniﬁcant were still revealed for t1/2, MRT0–24 h and Vd.
3.5. The AUC ratios between H-Nim and L-Nim in the two rat
groups
The AUC ratios between H-Nim and L-Nim at different time
intervals in 2-month-old and 9-month-old rats were shown in
Fig. 4. In general, except that the AUC0–4 h ratio between H-Nim
and L-Nim in 9-month-old rats was signiﬁcantly higher than that
in 2-month-old rats (Po0.05), the ratios of AUC0–8 h, AUC0–12 h
and AUC0–24 h between H-Nim and L-Nim were not signiﬁcantly
different between the two rat groups. For instance, the AUC0–4 h
ratio between H-Nim and L-Nim in 2-month-old rats (1.7270.66)
was 1.80-fold lower than that in 9-month-old rats (3.0970.95),
while the AUC0–24 h ratio between H-Nim and L-Nim in 2-month-
old rats (2.5070.44) just showed 1.31-fold lower than that in 9-
month-old rats (3.2871.34).Figure 4 The AUC ratios between L-Nim and H-Nim at different
time intervals in 2-month-old rats and 9-month-old rats. Data are
expressed as Mean7SD, n¼5. *Po0.05 compared to 2-month-
old rats.4. Discussion
4.1. Characterization of H-Nim and L-Nim by XRD and DSC
According to the results of XRD and DSC, both of H-Nim and
L-Nim showed well-resolved diffraction patterns with distinct
peaks and thermograms characteristic of each speciﬁc form, which
were in agreement with previously reported literatures19–21. It was
therefore conﬁrmed that H-Nim and L-Nim were properly formed,
which could be used for further studies.
4.2. The effect of polymorphism on the pharmacokinetics of Nim
According to the current data, the AUC0–24 h and Cmax of L-Nim
were signiﬁcantly higher than that of H-Nim in the two rat groups.
These results indicated that the absorption of L-Nim was higher
than that of H-Nim. As shown in the results of dissolution study,
the percentage of drug released of L-Nim was remarkably higher
than that of H-Nim. Furthermore, it was reported that differences
in solubility or dissolution kinetics usually caused differences in
bioavailability of polymorphs of the same compound22,23. There-
fore, the higher absorption of L-Nim was attributed to the higher
dissolution rate of it. It was speculated that these phenomena could
be explained by the different crystal structure of H-Nim and
L-Nim. As Grunenberg et al.18 reported, the H-Nim was theracemic compound which contained equimolar ratio of two
enantiotrophs in the crystal lattice, and the L-Nim was the
conglomerate compound which was the conglomerate of equimo-
lar physical mixture of pure enantiomers. It was presumed that the
crystal lattice of H-Nim could lead to lower dissolution rate due to
its high bond energy, and the L-Nim could be easy to be hydrated
in the dissolution medium and then presented a higher dissolution
rate. Additionally, the higher CL of H-Nim revealed that its
elimination was faster than that of L-Nim. It was reported that Nim
was a substrate for cytochrome P450 (CYP) enzymes24,25. More-
over, as Markel et al.26 reported, γ-glycine had higher biological
activity than α-glycine in ameliorating the behavioral disorders in
the genetic catalepsy strain after oral administration of two glycine
crystals. They concluded that this result may be related to
differences in the supramolecular complexes formed during the
interaction of the two polymorphs with biological liquids and the
drug receptors. Therefore, it was speculated that the binding
capacity of H-Nim and L-Nim to the active site of CYP enzymes
was different due to the different ability of forming supramolecular
complexes between receptors and clusters of Nim molecules
caused by the different crystal structure of H-Nim and L-Nim,
which then led to different elimination rate.
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The Cmax and AUC0–24 h of H-Nim and L-Nim in 9-month-old rats
were both lower than that in 2-month-old rats, which suggested
that the absorption of polymorphic Nim were decreased with
aging. As previous reported, Nim was well absorbed in the
gastrointestinal tract after oral administration27, while the basal
gastric blood ﬂow and the intestinal peristalsis were decreased in
elder individuals28–30. This could be the explanation for the
decline in the absorption of H-Nim and L-Nim in 9-month-old
rats. Nevertheless, the t1/2, CL, Vd and MRT0–24 h value of H-Nim
and L-Nim were not signiﬁcantly different between 2-month-old
and 9-month-old rats, which indicated the age-related changes in
the physiological state of kidney and liver have no signiﬁcant
effect on their elimination. It has been reported that activities of
CYP enzymes were preserved in normal aging31 and there were no
signiﬁcant differences in CYP3A4 activity between young and old
subjects32. Since CYP3A4, the major isozyme of CYP enzymes, is
responsible for the Nim metabolism24,25, this may be the reason
why the elimination of Nim was not signiﬁcantly different between
2- and 9-month old rats.
4.4. The differences of AUC ratios between H-Nim and L-Nim in
the two rat groups
The AUC ratios between H-Nim and L-Nim represented the
relative bioavailability of H-Nim and L-Nim after oral adminis-
tration. The AUC ratios between H-Nim and L-Nim presented in
Fig. 4 showed that this ratio was always larger than 1.0 in any
cases, which meant that L-Nim showed higher bioavailability if
compared to the H-Nim.
Compared to 2-month-old rats, the AUC ratios between H-Nim
and L-Nim at different time intervals in 9-month-old rats were
slightly increased especially for the ratio of AUC0–4 h, which meant
that the relative bioavailability of H-Nim and L-Nim between
2-month-old and 9-month-old rats were not signiﬁcantly different
but unparalleled. It was known that the impairment of gastrointest-
inal tract could result in the decreased absorption of polymorphic
Nim in 9-month-old rats28–30 and the degree of decreased absorption
of H-Nim was larger than that of L-Nim, while the activity of
CYP3A4 was not signiﬁcantly changed with aging31,32. Therefore,
although the lower concentration of polymorphic Nim in plasma
could be effectively metabolized by the hepatic CYP3A4, the degree
and rate of metabolism of H-Nim and L-Nim in 9-month-old rats
were not the same as in 2-month-old rats. As a result, the relative
bioavailability of H-Nim and L-Nim between 2-month-old and
9-month-old rats was unparalleled.5. Conclusions
This study showed that the pharmacokinetics of the polymorphic
Nim could be affected by the factor of age. An increased drug
absorption and bioavailability was found in younger rats than in
the elder rats for both H-Nim and L-Nim. The decreased drug
absorption in the elder rats may be attributed to the reduction of
basal gastric blood ﬂow and slower intestinal peristalsis. Since the
activities of CYP3A4 which is responsible for the elimination of
Nim rarely changed with aging, the elimination of both H-Nim and
L-Nim in rats of all ages kept nearly unchanged. Though an
increase in drug absorption of polymorphic Nim was found for
younger rats when compared to the elder rats, the unparalleledchange of the absorption and bioavailability of two different
crystal forms of polymorphic Nim caused by age differences
means that a further investigation is needed to understand the
deeper mechanism as how the drug absorption and elimination
were affected by aging. Anyhow, the results in this work are
valuable for the selection of suitable crystal form of polymorphic
drugs in dosage form design, clinical trial as well as the rational
clinical application.
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